Sugammadex 2 mg/kg

DRUG7 trials

Sponsors

Merck Sharp & Dohme LLC, University Hospital, Ghent, Poitiers University Hospital, Cukurova University

Conditions

AnesthesiaMorbid ObesityMorbidly Obese PatientsNeuromuscular BlockadeNeuromuscular Blockade Reversal AgentReversal of Neuromuscular Blockade

Phase 2

Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients

CompletedNCT01911520

University Hospital, GhentMorbidly Obese Patients

Start: 2011-01-31End: 2012-06-30Updated: 2021-07-13

Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients

CompletedNCT02545595

Poitiers University HospitalMorbid Obesity

Start: 2012-05-31Updated: 2016-10-12

Phase 3

Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)

CompletedNCT00421148

Merck Sharp & Dohme LLCAnesthesia

Start: 2005-05-30End: 2006-06-02Updated: 2019-01-28

Phase 4

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

CompletedNCT03346057

Merck Sharp & Dohme LLCReversal of Neuromuscular Blockade

Start: 2017-12-20End: 2019-09-04Updated: 2020-10-08

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

CompletedNCT03351608

Merck Sharp & Dohme LLCNeuromuscular Blockade

Start: 2018-02-12End: 2020-01-28Updated: 2021-02-05

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

CompletedNCT03909165

Merck Sharp & Dohme LLCNeuromuscular Blockade

Start: 2019-07-23End: 2023-09-21Updated: 2025-07-25

The Effect of Neostigmine and Sugammadex on the Optic Nerve Sheath Diameter

RecruitingNCT07666984

Cukurova UniversityNeuromuscular Blockade Reversal Agent

Start: 2026-06-04End: 2026-07-10Target: 86Updated: 2026-06-24

Related Papers

Sugammadex for Reversal of Neuromuscular Blockade in Neonates and Infants Less than 2 Years Old: Results from a Phase IV Randomized Clinical Trial

Anesthesiology2025-05-055 citations

Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study

Pediatric Anesthesia2021-12-0822 citations

A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants

BMC Anesthesiology2021-10-2814 citations